Investigators assessed disparities in patient access to therapies approved for the treatment of gastrointestinal malignancies in the United States, the United Kingdom, Europe, and Ireland, as well as benefit relative to cost.
This exploratory subgroup analysis of the TAGS study assessed the efficacy, safety, and quality of life (QOL) results observed in patients who received trifluridine/tipiracil or placebo in the third- or later-line settings.
Outcomes of lenvatinib-receiving patients who progressed to Child-Pugh B liver function within the first 8 weeks of treatment were compared with those of patients who maintained Child-Pugh A classification during the same time period.
Investigators present findings from a phase 1a study evaluating the safety and efficacy of MIV-818 in patients with hepatocellular carcinoma (HCC), hepatic cholangiocarcinoma (CCA), or liver metastases from solid tumors.
LEAP-005 investigators tested the safety and efficacy of combination lenvatinib and pembrolizumab in 32 patients with previously treated advanced non–microsatellite instability-high (MSI-H)/mismatch repair proficient (pMMR) colorectal cancer (CRC).
Investigators developed a clinical score to address how to categorize patients with well-differentiated neuroendocrine tumors (NETs) who are being considered for peptide receptor radionuclide therapy (PRRT) and how to sequence therapy.